Mallinckrodt (DB:MCD0) - Aandelenkoers, Nieuws & Analyse

MCD0 Overzicht aandelen

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.

Over het bedrijf

MCD0 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Risicoanalyse

Negatief eigen vermogen

Heeft geen betekenisvolle marktkapitalisatie ( €2M )

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Mallinckrodt plc Concurrenten

Biofrontera

XTRA:B8FK

€17.6m

SynBiotic

DUSE:SBX

€31.9m

Cantourage Group

XTRA:HIGH

€58.1m

Apontis Pharma

XTRA:APPH

€81.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mallinckrodt
Historische aandelenkoersen
Huidige aandelenkoers	€0.02
52 Week Hoogtepunt	€7.35
52 Week Laag	€0.02
Bèta	0
11 maand verandering	-97.74%
3 maanden verandering	-97.74%
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-99.73%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	MCD0	DE Pharmaceuticals	DE Markt
7D	-74.4%	-4.1%	-1.0%
1Y	n/a	-11.4%	16.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe MCD0 presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe MCD0 presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is MCD0's price volatile compared to industry and market?
MCD0 volatility
MCD0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.7%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

Stabiele aandelenkoers: De aandelenkoers van MCD0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van MCD0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1867	2,687	Siggi Olafsson	www.mallinckrodt.com

Mallinckrodt plc Samenvatting

Hoe verhouden de winst en inkomsten van Mallinckrodt zich tot de beurswaarde?
MCD0 fundamentele statistieken
Marktkapitalisatie	€1.60m
Inkomsten(TTM)	-€2.74b
Inkomsten(TTM)	€1.74b

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is MCD0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MCD0 resultatenrekening (TTM)
Inkomsten	US$1.89b
Kosten van inkomsten	US$1.25b
Brutowinst	US$640.60m
Overige uitgaven	US$3.61b
Inkomsten	-US$2.97b

Laatst gerapporteerde inkomsten

Sep 29, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-222.21
Brutomarge	33.97%
Nettowinstmarge	-157.55%
Schuld/Eigen Vermogen Verhouding	-34.4%

Hoe presteerde MCD0 op de lange termijn?

Bekijk historische prestaties en vergelijking

MCD0 Overzicht aandelen

Beloningen

Risicoanalyse

Mallinckrodt plc Concurrenten

XTRA:B8FK

€17.6m

DUSE:SBX

€31.9m

XTRA:HIGH

€58.1m

XTRA:APPH

€81.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Recent updates

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt plc Provides Earnings Guidance for the Year 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder

Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting

Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)

Mallinckrodt Reportedly Considers Sale of Opioid Business

Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index

NYSE American to Commence Delisting Proceedings Against Mallinckrodt

Mallinckrodt plc Filed for Bankruptcy

Mallinckrodt plc is Heading Towards Bankruptcy

Mallinckrodt plc Contemplates Bankruptcy

Second quarter 2023 earnings released

Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023

High number of new and inexperienced directors

Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc

Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

High number of new and inexperienced directors

Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released

High number of new and inexperienced directors

High number of new and inexperienced directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Mallinckrodt plc Samenvatting

0.0x

0.0x

Inkomsten en omzet